MaxCyte (MaxCyte) Change In Working Capital : $-3.55 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Change In Working Capital?

MaxCyte's change in working capital for the quarter that ended in Mar. 2024 was $-3.44 Mil.

MaxCyte's change in working capital for the fiscal year that ended in Dec. 2023 was $3.82 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

MaxCyte Change In Working Capital Historical Data

The historical data trend for MaxCyte's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Change In Working Capital Chart

MaxCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

1.61

-0.86

-1.65

-3.98

3.82

MaxCyte Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Working Capital	Get a 7-Day Free Trial															3.94	-2.41	-0.20	2.50	-3.44

MaxCyte Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.55 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

MaxCyte Change In Working Capital Related Terms

Thank you for viewing the detailed overview of MaxCyte's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte (MaxCyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

MXCT:UK MYE0:Germany MYE0:Germany

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Executives

John Joseph Johnston	director	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler	director, officer: President and CEO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross	officer: EVP, Global Sales	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky	officer: Chief Financial Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen	officer: Chief Scientific Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy	officer: Chief Financial Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud	officer: EVP and General Counsel	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz	officer: SVP and CAO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell	director	C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke	director	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Thompson J Stark Phd	director